Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Centessa Pharmaceuticals PLC ADR

CNTA
Current price
6.7 USD +0.7 USD (+11.67%)
Last closed 6 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 658 997 760 USD
Yield for 12 month +70.48 %
Week
Month
Year
CNTA
21.11.2021 - 28.11.2021

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom. Address: 1 Ashley Road, Altrincham, United Kingdom, WA14 2DT

Analytics

WallStreet Target Price

11 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

Last Year

Current Quarter

Last Quarter

Key Figures CNTA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -174 464 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -25.49 %
PEG Ratio
Return On Equity TTM -49.79 %
Wall Street Target Price 11 USD
Revenue TTM
Book Value 2.66 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings Share -1.65 USD
Diluted Eps TTM -1.65 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CNTA

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CNTA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CNTA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA 0.9343
Price Book MRQ 0.9842

Financials CNTA

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators CNTA

For 52 weeks

3 USD 8.65 USD
50 Day MA 6.48 USD
Shares Short Prior Month 1 370 673
200 Day MA 5.55 USD
Short Ratio 9.9
Shares Short 1 325 531
Short Percent 2.6 %